CN1267095C - Application use of dihydromyricetrin - Google Patents
Application use of dihydromyricetrin Download PDFInfo
- Publication number
- CN1267095C CN1267095C CNB031495729A CN03149572A CN1267095C CN 1267095 C CN1267095 C CN 1267095C CN B031495729 A CNB031495729 A CN B031495729A CN 03149572 A CN03149572 A CN 03149572A CN 1267095 C CN1267095 C CN 1267095C
- Authority
- CN
- China
- Prior art keywords
- dihydromyricetin
- group
- serum
- control group
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 claims abstract description 144
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 claims abstract description 70
- 239000003814 drug Substances 0.000 claims abstract description 14
- 210000004369 blood Anatomy 0.000 claims abstract description 13
- 239000008280 blood Substances 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 19
- 238000012360 testing method Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000015271 coagulation Effects 0.000 description 9
- 238000005345 coagulation Methods 0.000 description 9
- 208000006454 hepatitis Diseases 0.000 description 9
- 231100000283 hepatitis Toxicity 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000011550 stock solution Substances 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000002443 hepatoprotective effect Effects 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 7
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 6
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 6
- 206010067125 Liver injury Diseases 0.000 description 6
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 101710186708 Agglutinin Proteins 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 101710146024 Horcolin Proteins 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 101710189395 Lectin Proteins 0.000 description 4
- 101710179758 Mannose-specific lectin Proteins 0.000 description 4
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 4
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 4
- 239000000910 agglutinin Substances 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 210000004279 orbit Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- 241000219094 Vitaceae Species 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N flavone Chemical group O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
- 238000007445 Chromatographic isolation Methods 0.000 description 1
- 208000009701 Embryo Loss Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000011951 anti-virus test Methods 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- JWBPVFVNISJVEM-UHFFFAOYSA-M sodium caffeine benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C JWBPVFVNISJVEM-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses an application of dihydromyricetin in preparing medicine for decreasing blood fat or health-care products.
Description
The application is an application number: the dividing an application of 99119124.2 applications for a patent for invention.
The applying date of the application for a patent for invention of application number 99119124.2 is JIUYUE in 1999 16 days, and denomination of invention is " application of dihydromyricetin in the medicine of preparation treatment hepatitis etc. ".
Invention field
The invention belongs to the health care of treatment hepatitis, hepatoprotective, analgesia, blood fat reducing is eliminated the phlegm and the natural medicine field of anti-inflammation.
Background of invention
Document Walter Karrerr, Birkhauser Verlag, Bassel undStuttgart (1958), P.652, NO:1640 discloses the structural formula of dihydromyricetin,
But the activity of dihydromyricetin is not studied.
Detailed description of the present invention
The applicant is surprisingly found out that dihydromyricetin has treatment hepatitis, the hepatoprotective health care, and anti-inflammation, analgesia, blood fat reducing is eliminated the phlegm and the effect of enhance immunity systemic immunity power.Dihydromyricetin can be made pharmaceutical composition with pharmaceutical acceptable carrier or mixed with excipients.Dihydromyricetin can obtain from vitaceae.Also can obtain by the chemical field conventional method.
An object of the present invention is to provide a kind of pharmaceutical composition that contains dihydromyricetin and pharmaceutical acceptable carrier or excipient for the treatment of hepatitis.
Another object of the present invention provides the pharmaceutical composition that contains dihydromyricetin and pharmaceutical acceptable carrier or excipient that contains anti-inflammation.
A further object of the present invention provides a kind of pharmaceutical composition that contains dihydromyricetin and health product of hepatoprotective health care.
Another object of the present invention provides the pharmaceutical composition that contains dihydromyricetin and the health product of enhance immunity systemic immunity power.
Another object of the present invention provides the pharmaceutical composition that contains dihydromyricetin or the medicine for external use of anti-inflammatory analgesic.
Another object of the present invention provides the pharmaceutical composition that contains dihydromyricetin and the health product of blood fat reducing.
Another object of the present invention provides pharmaceutical composition and the health product that expectorant contains dihydromyricetin.
Another object of the present invention is a dihydromyricetin in preparation treatment hepatitis, hepatoprotective effect, and antiinflammatory, analgesia, blood fat reducing is eliminated the phlegm or is improved purposes in the pharmaceutical composition of immunity.
Dihydromyricetin can obtain like this: decoct vitaceae by all kinds of solvents (water and/or organic solvent), decoct one or many, decoction liquor is through concentrating cooling, standing over night, detection precipitates the active ingredient with supernatant, gets to have active precipitation, obtains crystal after chromatographic isolation.
Principle of the present invention is to follow the trail of the dihydromyricetin drug activity by setting up the pharmacological screening model, finds its pharmaceutical usage.The animal model test of the influence of the test of the influence of the mouse experiment liver damage that carbon tetrachloride is caused and mouse experiment liver damage that D-Gal is caused shows that dihydromyricetin has tangible hepatoprotective effect; Extracorporeal bacteria inhibitor test and and antivirus test show that dihydromyricetin has antibacterial and anti-inflammation functions; The test of serum agglutinin shows that dihydromyricetin has the effect of enhance immunity systemic immunity power.
Find that dihydromyricetin can be used for pharmaceutical field, field of health care products and field of food.
Dihydromyricetin can be directly medicinal or can be mixed with pharmaceutical composition with pharmaceutically acceptable carrier or mixed with excipients, and dihydromyricetin can also be as the effective ingredient of health product, and the present composition can also be mixed with beverage etc.
Pharmaceutical composition of the present invention can be mixed with pharmaceutical composition by conventional preparation technique of drug world and carrier.The present composition can be prepared into tablet, granule, and capsule, medicine for external use can also join in tea or the beverage, makes health tea or beverage.
The regular convention formula of tablet can be a dihydromyricetin: the 10-90% weight ratio, and lactose 90-10% weight ratio, sodium carboxymethyl cellulose 1.5g, magnesium stearate 0.5g, 50% ethanol is an amount of.The regular convention formula of electuary can be: dihydromyricetin 5-100% weight ratio, (sucrose+dextrin) 95-0% weight ratio, sucrose: dextrin=2: 1.Capsular regular convention formula can be: dihydromyricetin 10-100% weight ratio, starch 90-0% weight ratio.But those skilled in the art also can be mixed with other dosage form with technology well known in the art and carrier as required.
Describe the present invention in detail by the following examples.But should be appreciated that these embodiment just illustrate the present invention, rather than in office where face limits the scope of the invention.
Embodiment 1: tablet:
Dihydromyricetin 25g,
Lactose 53g,
Sodium carboxymethyl cellulose 1.5g,
Magnesium stearate 0.5g,
50% ethanol 5ml
Said components is mixed the back compacting in flakes in mixer.
Embodiment 2: syrup
1 part of weight of dihydromyricetin,
2.5 parts of weight of sucrose,
1.25 parts of weight of dextrin,
5 parts of weight of ethanol
Mix mentioned component and obtain syrup.
Embodiment 3: electuary
Dihydromyricetin 115g,
Icing Sugar 345g,
Dextrin 145g,
Ethanol 5ml
Said components is mixed after drying, obtains electuary.
Embodiment 4: capsule
Dihydromyricetin 100g,
Starch 20g,
Behind the said components mix homogeneously, incapsulate.
Embodiment 5: the influence of the mouse test liver damage that dihydromyricetin causes carbon tetrachloride:
Animal is divided into six groups at random: three groups of normal control groups, positive controls, model control group, dihydromyricetin group: 100mg/kg, 200mg/kg, 400mg/kg.The normal control group is that animal is not given any medicine, only gives solvent; Positive controls is bifendate 200mg/kg, qdx6, and po, bifendate is treating hepatitis medicine commonly used, with bifendate treatment animal pattern, observe the curative effect, in contrast; Model control group is the check drug effect, and animal must be made hepatitis model earlier, makes animal suffer from hepatitis; The dihydromyricetin group is on above-mentioned model basis, gives dihydromyricetin again, and with observe the curative effect, three groups all is Bidx6 po.Each treated animal grouping administration, every group of 10 mices, twice on the one, take volume 0.5ml/20g mice, took continuously six days, 0.2ml/ mice of 1 hour lumbar injection l% carbon tetrachloride oil solution after the last administration, on an empty stomach after 16 hours by the eye socket venous blood collection, separation of serum, the SGPT (ALT) of mensuration serum, SGOT (AST) content and serum total bilirubin (T-BIL caffeine sodium benzoate colorimetry) content, and and positive controls, the normal control group, model control group relatively, model control group is taken the equivalent coordinative solvent, positive controls adopts bifendate 200mg/kg, pox6, once a day.The results are shown in Table 1.
Table 1 dihydromyricetin causes the variation of the serum SGOT of mouse liver injury to carbon tetrachloride
| Group | Dosage mg/kg | Serum SGPT (U) X ± SD | Serum SGOT (U) X ± SD | T-BIL |
| Coordinative solvent | ||||
| Model control group | Coordinative solvent | 109.2_9.8 | 83.7±4.6 | 5.78±2.91 |
| Dihydromyricetin | 50Bidx6po | 108.3_10.12 | 79.4±10.3 | |
| Dihydromyricetin | 100Bidx6po | 85.3_4.34 | 71.0±10.4 | 4.24±2.11 |
| Dihydromyricetin | 200Bidx6po | 68.3_4.89* | 68.4±9.2** | 3.42±1.32 |
| Bifendate | 200qdx6po | 63.64.10** | 61.2±4.2** | 3.12±1.24 |
* compare with model group P＜0.05 * * P＜0.01
From the effect of dihydromyricetin with excellent treatment hepatitis as can be seen of the data of table 1.And reduce T-BIL content, show the hepatoprotective effect of dihydromyricetin with tangible reducing enzyme and treating jaundice.
Embodiment 6: dihydromyricetin causes the protective effect of mouse liver injury to D-galactosamine
Animal is divided into six groups at random, and positive controls, model control group, normal control group, dihydromyricetin component are three groups: 100mg/kg, and 200mg/kg, 400mg/kg, the meaning of each group is with above-mentioned embodiment 4.Normal control group, model control group are taken corresponding solvent, positive controls lumbar injection 200mg/kg, pox6, qd, 1 hour D-galactosamine 100mg/kg gets blood by eye socket after 16 hours, separation of serum after the last administration, measure serum SGPT, the variation of serum SGOT the results are shown in Table 2
Table 2 dihydromyricetin causes the serum SGPT of mouse liver injury, the variation of SGOT to D-galactosamine
| Group | Dosage mg/kg | Serum SGPT (U) X Xu D | Serum SGOT (U) X Xu D |
| The normal control group | Coordinative solvent | ＜40 | 33.7_4.7 |
| Model control group | Coordinative solvent | 90.7_17.3 | 58.3_15.5 |
| Dihydromyricetin | 50Bidx6po | 48 | 50 |
| Dihydromyricetin | 100Bidx6po | 34_12.8 | 41.2_11.0 |
| Dihydromyricetin | 200Bidx6po | 22.4** | 31.8* |
| Bifendate | 200qdx6po | 23.6_3.9** | 33.8_15.2* |
* P＜0.05, * * P＜0.01 and model group comparison
From the data of table 2 as can be seen dihydromyricetin have fabulous hepatoprotective effect.
Embodiment 7: dihydromyricetin is tested at external antibacterial, antiviral:
Separation of influenza virus and mirror (dripping) are fixed
Embryo Gallus domesticus at present commonly used separates and carries out influenza virus, and route of inoculation is the allantoic cavity of Embryo Gallus domesticus, occurs the characteristics of lesion of back chicken embryo death after 3 days and hemagglutinin occurs, and to this, we adopt the method to carry out evaluation to dihydromyricetin.We adopt the influenza virus of certain density extracting solution and 4 HAUs to mix at 1: 1, allow the two inject Embryo Gallus domesticus after 20 minutes again in the room temperature effect, and injection volume is every embryo 0.2ml.The Embryo Gallus domesticus of 9 to 11 ages in days is adopted in experiment, carry out the allantoic cavity inoculation, cultivate after 48 hours, placed liquid in 4 ℃, aseptic then its urine of getting, get supernatant through 1000rpm after centrifugal 10 minutes, packing is deposited for-20 ℃, the usefulness that is equipped with detection, the detection of urine divides blood clotting and blood to press down two kinds, and the erythrocyte of use comes prosperous cock, and method is a conventional method.
The antiviral experiment: the dihydromyricetin with variable concentrations carries out the antiviral experiment in Embryo Gallus domesticus
Table 3 hirst's hemagglutination inhibition test
| The serum dilution sample concentration | Stock solution | 10 × | 20 × | 40 × | 80 × | 160 × | 320 × | 640 × | 128 0× |
| Stock solution 1 | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | ++ | ||
| Stock solution 2 | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | ++ | ||
| Stock solution 3 | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | +++ + | ++ | |
| Stock solution 4 | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | +++ + | ++ | |
| 10 -5a | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | +++ + | +++ + | ++ |
| 10 -5b | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | +++ + | +++ + | ++ |
| 10 -5c | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | ++ | +++ + | |
| 10 -5d | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | +++ + | ++ | |
| 10 -6a | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | ++ | +++ + |
| 10 -6b | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | ++ | +++ + | |
| 10 -6c | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | +++ + | ++ | |
| 10 -6d | +++ + | ++ ++ | ++ ++ | +++ + | ++ ++ | +++ + | +++ + | ++ |
Remarks: 1, stock solution refers to the dihydromyricetin 4mg/ml of initial concentration
2,10
-5With 10
-6Finger carries out the dilution factor of medicine from dihydromyricetin stock solution
3, during result of determination by blood clotting intensity respectively with ++ ++, +++, ++ ,-expression coagulation appears with 50% erythrocyte ++ the blood clotting dilution factor be its blood clotting decline
Erythrocyte is the invalid main aperture of fine sand grain sample (pipe) end person +++, i.e. 100% coagulation; Erythrocyte evenly is laid on the end, hole (pipe), but the edge is whole to hole (pipe) end concentrator is not slightly +++, i.e. 75% coagulation; (pipe) end, form a ring-type to erythrocyte in the hole, has little coagulation piece person to be all around ++, i.e. 50% coagulation; (pipe) end, form wad to erythrocyte in the hole, but the edge is smooth inadequately, have slightly all around coagulation piece person for+, i.e. 25% coagulation; (pipe) end, form wad to erythrocyte in the hole, and the smooth neat person in edge is one, does not promptly have coagulation.
Embodiment 8: external bacteriostasis test:
The external inhibitory effect test of dihydromyricetin:
Adopt dull and stereotyped punch method to measure the antimicrobial effect of extract.After test tube method and dull and stereotyped punch method are attempted, determined this short method simple and easy to do and consuming time of dull and stereotyped punch method.Adopt five kinds of experimental strains: staphylococcus aureus, escherichia coli, streptococcus pneumoniae, hemolytic chain bacterium,
Table 4 micrococcus catarrhalis carries out effect test.
| The experimental group strain name | Stock solution | 1 times of dilution of extracting solution | Multi-resistance (penicillin and streptomycin, nystatin) |
| Staphylococcus aureus | 9.5mm | 8mm | 17-20mm |
| Escherichia coli | 8.5mm | 6mm | 11mm |
| Streptococcus pneumoniae | - | - | 10mm |
| The hemolytic chain bacterium | - | - | 10-11mm |
| The mucositis fungus ball | - | - | 11mm |
Stock solution refers to the dihydromyricetin 4mg/ml of initial concentration
Remarks: mm refers to the diameter of inhibition zone
Embodiment 9:
Dihydromyricetin influences mouse humoral immune (serum agglutinin)
1, negative control group
2, aspirin group
3, dihydromyricetin of the present invention is heavy dose of organizes (0.15g/kg, big-1.35g/kg, dosage group 0.45g/kg)
Observe the coagulation degree, divide five groups (0-4), calculating antibody result carries out statistical procedures,
Be calculated as follows the antibody product
(antibody product ∑=S1+2S2+3S3+4S4 ... NSn)
Table 5, dihydromyricetin of the present invention are to the influence of mice agglutinin
| Number of animals | The antibody product | The P value | |
| The blank group | 10 | 93.4±13.22 | |
| Aspirin | 10 | 115.00± 17.31 | ＜0.01 |
| The dihydromyricetin small dose group | 10 | 103±11.31 | |
| Middle dosage group | 10 | 115.92± 19.38 | ＜0.01 |
| Heavy dose of group | 10 | 103±7.01 | ＜0.05 |
The result confirms: middle and high dosage group obviously increases anti-sheep red blood cell agglutinin value in the serum, and significant difference is arranged, and the dihydromyricetin higher dosage has potentiation to system's phagocytic function in the body dictyosome.
Embodiment 10
The dihydromyricetin analgesic experiment
1, animal target: Kunming white mice 18～22g male and female half and half
2, grouping and solution preparation:
With 10 every group of white mice, be divided into 5 groups: 1. normal saline group; 2. water extraction group (0.26g/ml); 3. alcohol extract (0.21g/ml); 4. total flavones group (0.15g/ml); 5. dihydromyricetin (0.04g/ml).
3, administering mode
Weigh to each group white mice, by every 0.1ml/10g administration, continuous three days gastric infusions, and open 60min after the administration in per 3 days, the abdominal cavity only feeds acetic acid (0.5%) solution 0.2ml/, observes in 5～30min animal and sweeps the body number.
4, result and statistics
| The medicine name | Dosage | The pain relieving rate | The P value |
| Normal saline water is put forward group alcohol extraction group total flavones group dihydromyricetin group | 0.2ml/ 2.6g/kg 2.1g/kg 1.5g/kg 0.4g/kg only | 0 88.1％ 93.5％ 88.0％ 54.1％ | P＜0.05 P＜0.05 P＜0.05 P＜0.05 |
The result proves: dihydromyricetin has tangible analgesic effect.
Embodiment 11
Dihydromyricetin is to the effect for reducing fat of hyperlipidemia mice blood fat
| Group | Dosage mg/kg | TC (mmol/L ) | TG (mmol/ L) | HDL-C (mmol/L ) |
| Normal control group model matched group clofibrate dihydromyricetin | 310 400 | 3.91± 0.78 11.24± 5.79 5.12± 1.14 6.11± 1.90 | 1.41± 0.37 2.11± 0.41 1.76± 0.11 1.58± 0.2 | 1.85± 0.28 1.35± 0.52 1.72± 0.64 1.621± 0.56 |
Animal is divided into 4 groups at random, normal control group, positive controls, model control group, extracting solution group.Every group of 10 mices, once-a-day, successive administration 10 days, the normal control group is not given any medicine.All only respectively organize mice in fact, form experimental hyperlipidemia to high lipoprotein emulsion 0.5ml/.Overnight fasting after medication in 10 days.Next day is from the mouse orbit extracting vein blood.Press enzyme process and detect serum total cholesterol (TC), triglyceride (TG), HDL-C (HDL-C) content.The result shows, the model control group serum TC, and the TG value obviously raises, and the HDL-C value descends.Compare with model control group.The dihydromyricetin group can obviously reduce serum TC, and the TG value also makes HDL-C slightly raise.Illustrate that this extract can suppress the mice blood fat rising that high lipoprotein emulsion causes, has effect for reducing fat.
Embodiment 12
Dihydromyricetin is to the phenol red expectorant test of mice
Experimental technique:
Animal oral test every day sample 1 time, continuous oral three days.Being subjected to test product dosage is 100/kg, and the administration group is pressed the 20ml/kg administration, and negative control group is oral with the volume normal saline.Last administration fasting in preceding 1 day, 0.5 hour lumbar injection 25% phenol red solution 500mg/kg after the last administration, press neck again after 0.5 hour and put to death animal separation trachea, insert entry needle, use the 2ml normal saline flushing, flushing liquor adds 1M NaOH 0.1ml colour developing, in 546mm wavelength colorimetric, directly reads phenol red content with 722 type spectrophotometers.
The table below: represent that from result of the test the dihydromyricetin sample increases the phenol red secretory volume in mouse breathing road after oral 3 days, the prompting sample has phlegm-dispelling functions.
Table 1, dihydromyricetin are to the influence of the phenol red expectorant test of mice
| Sample | Dosage mg/kg | Phenol red amount (increasing percentage rate ug/ml) | |
| (X±SD)％ | |||
| The dihydromyricetin dihydromyricetin | 20ml/kg 100 | 0.68±0.22 0.70± 0.17* | - - |
* P＞0.05, * * P＜0.05, * * * P＜0.01 are with physiology saline group relatively.
Claims (2)
- Dihydromyricetin the preparation blood fat reducing medicine in purposes.
- Dihydromyricetin the preparation blood fat reducing health product in purposes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031495729A CN1267095C (en) | 1999-09-16 | 1999-09-16 | Application use of dihydromyricetrin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031495729A CN1267095C (en) | 1999-09-16 | 1999-09-16 | Application use of dihydromyricetrin |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 99119124 Division CN1131029C (en) | 1999-09-16 | 1999-09-16 | Application of dihydromyricetin in preparation of medicines for treating hepatitis etc. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1596887A CN1596887A (en) | 2005-03-23 |
| CN1267095C true CN1267095C (en) | 2006-08-02 |
Family
ID=34659759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031495729A Expired - Fee Related CN1267095C (en) | 1999-09-16 | 1999-09-16 | Application use of dihydromyricetrin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1267095C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105663180A (en) * | 2016-01-27 | 2016-06-15 | 浙江大学 | Application of waxberry extract in preparation of functional food or drug |
| CN118453573A (en) * | 2024-05-08 | 2024-08-09 | 华中农业大学 | Application of dihydromyricetin-DHA in the preparation of drugs for treating type 2 diabetes |
-
1999
- 1999-09-16 CN CNB031495729A patent/CN1267095C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1596887A (en) | 2005-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1116293C (en) | Preparation and application of dihydromyricetrin | |
| CN1293101C (en) | White fungus polysaccharide and its preparation method as well as medicament composition with the compound as active constituent | |
| CN1397560A (en) | Process for extracting general platycodoside and platycoligenin D from platycodon root, its medical application and its Chinese medicine | |
| CN1267095C (en) | Application use of dihydromyricetrin | |
| CN1256942C (en) | Application of dihydromyricetrin | |
| CN1943689A (en) | A Chinese traditional medicinal composition for treatment of wind-heat type common cold and its preparation method | |
| CN1273496C (en) | Polysaccharose MF4 of mussel with enhancing immunity and anti-tumour activity | |
| CN1131029C (en) | Application of dihydromyricetin in preparation of medicines for treating hepatitis etc. | |
| CN1141101C (en) | Chinese medicine for treating hepatitis B and its preparing process | |
| CN1806821A (en) | Rhinitis-treating medicine | |
| CN1397567A (en) | Spiruline polyose, its extraction process and it medical application in increasing white cells and treating cancer | |
| CN1244332C (en) | Sarcandra extract and its application | |
| CN1375289A (en) | Ampelosis general flavone composition with liver protecting function | |
| CN1453295A (en) | Medicinal polysaccharide component of spinulate hedgehog fungus, its prepn and medicinal composition | |
| CN1094052C (en) | Anticancer goose blood preparation | |
| CN1723956A (en) | Medicine for treating chronic gastritis and gastric carcinoma, and its prepn. method | |
| CN1279912C (en) | Use of sinomenine | |
| CN1883500A (en) | Application of low molecular weight citrus pectin in increasing immunity | |
| CN1748736A (en) | New medicine administration path for reducing heat and detoxicating injection an dits preparing process | |
| CN1316980C (en) | Medicinal use of spanish moss of Chinese traditional medicine | |
| CN1785392A (en) | Chinese medicinal composition for treating prostatitis and its preparation method | |
| CN101966245B (en) | Compound injection for curing viral diseases in livestock and poultry and preparation method thereof | |
| CN1730014A (en) | Novel drug administration route of semen armeniacae amarum injection, its preparation process and new indications | |
| CN1864740A (en) | A Chinese medicinal composition for clearing heat and expelling toxin and preparation method thereof | |
| CN1803155A (en) | Medicine for curing rhinitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060802 Termination date: 20180916 |